Aclys Bio Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
2
- Latest Deal Type
-
2ndary - Private
- Investors
-
3
Aclys Bio General Information
Description
Developer of precision biologics designed for the treatment of cancer. The company identifies a set of novel precision and immune-oncology targets from the tumour molecular profiles of tens of thousands of cancer patients and is building antibody-based therapies against each target, both for internal development and for partnership, enabling clinicians to decrease clinical trial times, costs, and risk, while improving trial success rates and ultimately, patient lives.
Contact Information
Website
www.aclys.bioCorporate Office
- 16 Cavendish Court
- Suite 408
- Lebanon, NH 03766
- United States
Corporate Office
- 16 Cavendish Court
- Suite 408
- Lebanon, NH 03766
- United States
Aclys Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Secondary Transaction - Private | Completed | Pre-Clinical Trials | ||||
| 4. Accelerator/Incubator | Completed | Pre-Clinical Trials | ||||
| 3. Grant | 01-Jul-2022 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 10-Dec-2019 | $1.5M | $1.5M | Completed | Pre-Clinical Trials | |
| 1. Grant | 10-May-2019 | $294K | Completed | Pre-Clinical Trials |
Aclys Bio Patents
Aclys Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023215746-A2 | Anti-alppl2 antibodies and chimeric antigen receptors, and compositions and methods of use | Inactive | 02-May-2022 | ||
| WO-2023215746-A3 | Anti-alppl2 antibodies and chimeric antigen receptors, and compositions and methods of use | Inactive | 02-May-2022 | ||
| WO-2023215746-A9 | Anti-alppl2 antibodies and chimeric antigen receptors, and compositions and methods of use | Inactive | 02-May-2022 | ||
| JP-2025066746-A | Anti adam12 antibody and chimeric antigen receptor, and composition and method including the same | Pending | 20-Mar-2019 | ||
| CA-3133633-A1 | Anti-adam12 antibodies and chimeric antigen receptors, and compositions and methods comprising | Pending | 20-Mar-2019 | C07K16/40 |
Aclys Bio Signals
Aclys Bio Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| National Institutes of Health | Government | |||
| National Cancer Institute | Government | |||
| DRIVEN Accelerator Hub | Accelerator/Incubator |
Aclys Bio FAQs
-
When was Aclys Bio founded?
Aclys Bio was founded in 2017.
-
Where is Aclys Bio headquartered?
Aclys Bio is headquartered in Lebanon, NH.
-
What is the size of Aclys Bio?
Aclys Bio has 2 total employees.
-
What industry is Aclys Bio in?
Aclys Bio’s primary industry is Biotechnology.
-
Is Aclys Bio a private or public company?
Aclys Bio is a Private company.
-
What is Aclys Bio’s current revenue?
The current revenue for Aclys Bio is .
-
How much funding has Aclys Bio raised over time?
Aclys Bio has raised $1.5M.
-
Who are Aclys Bio’s investors?
National Institutes of Health, National Cancer Institute, and DRIVEN Accelerator Hub have invested in Aclys Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process